Edgar Filing: Evoke Pharma Inc - Form 4

Evoke Phan Form 4										
December							OMB A	APPROVAL		
FOR	VI 4 UNITED					COMMISSION				
Check	this box	W	Washington, D.C. 20549				Number:	3235-0287		
if no lo subject Section Form 4 Form 5 obligati may co	nger to 16. or Filed put	rsuant to Section	SECUF 16(a) of th Utility Hol	RITIES ne Securit: ding Corr	ies Exchan pany Act	WNERSHIP OF nge Act of 1934, of 1935 or Sectio 940	January 31, 2005 average urs per 0.5			
(Print or Type	e Responses)									
1. Name and CARLSO	Symbo	er Name and Pharma Ir			5. Relationship of Reporting Person(s) to Issuer					
(Last)	(First) (of Earliest T	-	x j	(Check all applicable)				
C/O EVO	KE PHARMA, IN ANTA FE DRIVI	(Month) C., 505 12/02	/Day/Year)	luisuetton		Director X Officer (give below) Chief				
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SOLANA	BEACH, CA 920	75				Form filed by M Person	Aore than One F	Reporting		
(City)	(State)	(Zip) Ta	ble I - Non-I	Derivative S	Securities A	cquired, Disposed o	f, or Beneficia	ally Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code		(A) or of (D)	SecuritiesHBeneficially(Owned(5. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	eport on a separate line	e for each class of se	curities benef	ficially own	ed directly o	or indirectly.				
				inform require	ation cont ed to respo ys a currei	spond to the collect tained in this form ond unless the for ntly valid OMB cor	are not m	SEC 1474 (9-02)		
	Tab	le II - Derivative So (e.g., puts, ca				Beneficially Owned securities)				
		saction Date 3A. Do /Day/Year) Execu		4. Transactio	5. Number orDerivative			7. Title and Amount of Underlying Securities		

Edgar Filing: Evoke Pharma Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, a 5)	(D)	(Month/Day/Year)		(Instr. 3 and	4)	
				Code V	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 8.67	12/02/2013		А	100,000		<u>(1)</u>	12/01/2023	Common Stock	100,000	
Reporting Owners											

Relationships **Reporting Owner Name / Address** 10% Owner Officer Other Director CARLSON MARILYN R. C/O EVOKE PHARMA, INC. Chief Medical Officer 505 LOMAS SANTA FE DRIVE, SUITE 270 SOLANA BEACH, CA 92075 Signatures /s/ Matthew J. D'Onofrio, Attorney-in-fact for Marilyn R. 12/03/2013 Carlson **Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 25% of the total number of shares of common stock subject to the option shall vest on December 1, 2014, and the remainder will vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service to the Issuer through each such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.